Stem Cell Research Center, RNL BIO, Seoul, 153-768, Republic of Korea.
J Transl Med. 2011 Oct 21;9:181. doi: 10.1186/1479-5876-9-181.
Prolonged life expectancy, life style and environmental changes have caused a changing disease pattern in developed countries towards an increase of degenerative and autoimmune diseases. Stem cells have become a promising tool for their treatment by promoting tissue repair and protection from immune-attack associated damage. Patient-derived autologous stem cells present a safe option for this treatment since these will not induce immune rejection and thus multiple treatments are possible without any risk for allogenic sensitization, which may arise from allogenic stem cell transplantations. Here we report the outcome of treatments with culture expanded human adipose-derived mesenchymal stem cells (hAdMSCs) of 10 patients with autoimmune associated tissue damage and exhausted therapeutic options, including autoimmune hearing loss, multiple sclerosis, polymyotitis, atopic dermatitis and rheumatoid arthritis. For treatment, we developed a standardized culture-expansion protocol for hAdMSCs from minimal amounts of fat tissue, providing sufficient number of cells for repetitive injections. High expansion efficiencies were routinely achieved from autoimmune patients and from elderly donors without measurable loss in safety profile, genetic stability, vitality and differentiation potency, migration and homing characteristics. Although the conclusions that can be drawn from the compassionate use treatments in terms of therapeutic efficacy are only preliminary, the data provide convincing evidence for safety and therapeutic properties of systemically administered AdMSC in human patients with no other treatment options. The authors believe that ex-vivo-expanded autologous AdMSCs provide a promising alternative for treating autoimmune diseases. Further clinical studies are needed that take into account the results obtained from case studies as those presented here.
预期寿命的延长、生活方式和环境的变化导致发达国家的疾病模式发生变化，退行性疾病和自身免疫性疾病的发病率不断上升。干细胞通过促进组织修复和防止与免疫攻击相关的损伤，已成为治疗这些疾病的一种有前途的工具。患者来源的自体干细胞是这种治疗的安全选择，因为它们不会引起免疫排斥，因此可以进行多次治疗，而不会有同种异体干细胞移植引起的同种异体致敏的风险。在这里，我们报告了对 10 名自身免疫相关组织损伤且治疗选择有限的患者进行培养扩增的人脂肪来源间充质干细胞（hAdMSC）治疗的结果，这些患者包括自身免疫性听力损失、多发性硬化症、多发性肌炎、特应性皮炎和类风湿性关节炎。为了进行治疗，我们开发了一种标准化的 hAdMSC 培养扩增方案，从少量脂肪组织中获得足够数量的细胞，以进行重复注射。从自身免疫患者和老年供体中常规获得高扩增效率，而安全性、遗传稳定性、活力和分化潜能、迁移和归巢特性没有可测量的损失。尽管从同情使用治疗中得出的关于治疗效果的结论只是初步的，但这些数据为在没有其他治疗选择的情况下，对患有自身免疫性疾病的人类患者进行系统性 AdMSC 治疗的安全性和治疗特性提供了令人信服的证据。作者认为，体外扩增的自体 AdMSC 为治疗自身免疫性疾病提供了一种有前途的替代方法。需要进一步的临床研究，考虑到这里呈现的病例研究结果。
